Craig-Hallum analyst Matt Hewitt maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today. The company’s shares closed last Friday at $18.03.
According to TipRanks, Hewitt is an analyst with an average return of -1.5% and a 44.64% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Avid Bioservices, Inotiv, and Apyx Medical.
Currently, the analyst consensus on BioLife Solutions is a Strong Buy with an average price target of $23.60.
The company has a one-year high of $24.50 and a one-year low of $8.92. Currently, BioLife Solutions has an average volume of 392.8K.
Based on the recent corporate insider activity of 170 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
